Stephen Nava

Corporate Officer/Principal en Regulator Affairs Quality Assurance Consulting Services, Inc. .

Health Technology

Consumer Services

Cargos activos de Stephen Nava

Empresas	Cargo	Inicio	Fin
Regulator Affairs Quality Assurance Consulting Services, Inc.	Corporate Officer/Principal	01/01/2004	-

Empresas	Cargo	Inicio	Fin
BiPar Sciences, Inc. BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ.	Consejero General	01/01/2005	01/06/2011
Acumen Sciences LLC	Consejero General	01/01/2002	01/01/2004
VIRACTA THERAPEUTICS, INC.	Oficial de Cumplimiento	09/07/2018	-
VIRACTA THERAPEUTICS, INC.	Consejero General	09/07/2018	-

Texas A&M University-Kingsville

Undergraduate Degree

Internacional

Estados Unidos

Operativa

Sectorial

Health Technology	3
Consumer Services	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas privadas	4
Sunesis Pharmaceuticals, Inc. Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.	Health Technology
BiPar Sciences, Inc. BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ.	Health Technology
Acumen Sciences LLC
Regulator Affairs Quality Assurance Consulting Services, Inc.